(Q56944494)

2

David J Moliterno

0 references

Deepak L. Bhatt

9

Deepak L Bhatt

0 references

Peter B. Berger

3

Peter B Berger

0 references

Gregg W Stone

4

Gregg W Stone

0 references

Kathy Wolski

8

Kathy Wolski

0 references

Steven J Yakubov

6

Steven L Yakubov

0 references

Peter M DiBattiste

5

Peter M DiBattiste

0 references

Shelly K. Sapp

7

Shelly K Sapp

0 references

author name string

Albert W Chan

Journal of the American College of Cardiology

1

0 references

language of work or name

English

0 references

publication date

October 2003

0 references

published in

0 references

volume

42

0 references

issue

7

0 references

page(s)

1188-1195

0 references

cites work

Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

1 reference

7 January 2021

Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Clopidogrel versus ticlopidine after intracoronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021

Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900944-6

7 January 2021